38 related articles for article (PubMed ID: 29137966)
1. Ten-year clinical outcomes of polymer-free versus durable polymer new-generation drug-eluting stent in patients with coronary artery disease with and without diabetes mellitus : Results of the Intracoronary Stenting and Angiographic Results: Test Efficacy of Sirolimus- and Probucol- and Zotarolimus-Eluting Stents (ISAR-TEST 5) trial.
Koch T; Lenz T; Joner M; Xhepa E; Koppara T; Wiebe J; Coughlan JJ; Aytekin A; Ibrahim T; Kessler T; Cassese S; Laugwitz KL; Schunkert H; Kastrati A; Kufner S;
Clin Res Cardiol; 2021 Oct; 110(10):1586-1598. PubMed ID: 34156521
[TBL] [Abstract][Full Text] [Related]
2. Prospective study to evaluate safety and efficacy of Zotarolimus Eluting Stent (PSEZES) in patients with long coronary artery lesions.
Bahuleyan CG; Krishna Kumar VV; Babu S
Indian Heart J; 2015; 67(3):233-8. PubMed ID: 26138180
[TBL] [Abstract][Full Text] [Related]
3. Control of diabetes mellitus and the risk of neointimal hyperplasia after percutaneous coronary intervention: Post-hoc analysis from the BLADE-PCI trial.
Jonas M; Genereux P; Maehara A; Ben-Yehuda O; Stone GW; Chernin G
Atherosclerosis; 2024 Jul; 394():117264. PubMed ID: 37726192
[TBL] [Abstract][Full Text] [Related]
4. A technology evaluation of the Onyx Frontier drug-eluting stent.
Leone PP; Assafin M; Scotti A; Gonzalez M; Mignatti A; Dawson K; Rauch J; Khaliq A; Bliagos D; Latib A
Expert Opin Drug Deliv; 2023 May; 20(5):689-701. PubMed ID: 37203200
[TBL] [Abstract][Full Text] [Related]
5. Coronary stent implantation links to the occurrence of eosinophilia and interstitial pneumonia: a case report and systematic review.
Zhang F; Wang W; Zhu Y; Mao Y; Wang T; Gao P
BMC Pulm Med; 2024 Jun; 24(1):281. PubMed ID: 38886703
[TBL] [Abstract][Full Text] [Related]
6. Ultrathin Strut Biodegradable Polymer-Coated Sirolimus-Eluting Coronary Stents: Patient-Level Pooled Analysis From Two Indian Registries.
Babu Pothineni R; Ajmera P; Chawla KK; Mantravadi SS; Pathak A; Inamdar MK; Jariwala PV; Vijan V; Vijan V; Potdar A
Cureus; 2023 Jul; 15(7):e41743. PubMed ID: 37575772
[TBL] [Abstract][Full Text] [Related]
7. One-year outcomes of polymer-free amphilimus-eluting stents versus durable polymer zotarolimus-eluting stents in patients with diabetes mellitus: a meta-analysis.
Wang H; Xie X; Zu Q; Lu M; Chen R; Yang Z; Gao Y
Cardiovasc Diabetol; 2022 Oct; 21(1):220. PubMed ID: 36307791
[TBL] [Abstract][Full Text] [Related]
8. Clinical outcomes of ultrathin biodegradable polymer-coated sirolimus-eluting stents in an all-comer population: One-year results from the T-FLEX registry including high-risk subgroups.
Pothineni RB; Vijan V; Potdar A; Inamdar MK; Pathak A; Mantravadi SS; Ajmera P
Anatol J Cardiol; 2021 Oct; 25(10):706-715. PubMed ID: 34622785
[TBL] [Abstract][Full Text] [Related]
9. One-year clinical outcomes of patients treated with polymer-free amphilimus-eluting stents or zotarolimus-eluting stents: A propensity-score adjusted analysis.
Rozemeijer R; van Muiden IG; Koudstaal S; Leenders GE; Timmers L; Rittersma SZ; Kraaijeveld AO; Doevendans PA; Voskuil M; Stella PR
Catheter Cardiovasc Interv; 2019 Jul; 94(1):61-69. PubMed ID: 30604493
[TBL] [Abstract][Full Text] [Related]
10. Comparing Stent Thrombosis associated with Zotarolimus Eluting Stents versus Everolimus Eluting Stents at 1 year follow up: a systematic review and meta-analysis of 6 randomized controlled trials.
Bundhun PK; Yanamala CM; Huang WQ
BMC Cardiovasc Disord; 2017 Mar; 17(1):84. PubMed ID: 28302055
[TBL] [Abstract][Full Text] [Related]
11. A comparison of the ultrathin Orsiro Hybrid sirolimus-eluting stent with contemporary drug-eluting stents: A meta-analysis of randomized controlled trials.
Lipinski MJ; Forrestal BJ; Iantorno M; Torguson R; Waksman R
Cardiovasc Revasc Med; 2018 Jan; 19(1 Pt A):5-11. PubMed ID: 29221958
[TBL] [Abstract][Full Text] [Related]
12. Clinical outcomes of complex real-world diabetic patients treated with amphilimus sirolimus-eluting stents or zotarolimus-eluting stents: A single-center registry.
Rozemeijer R; Benedetto D; Kraaijeveld AO; Voskuil M; Stein M; Timmers L; Rittersma SZ; Agostoni P; Doevendans PA; Stella PR
Cardiovasc Revasc Med; 2018 Jul; 19(5 Pt A):521-525. PubMed ID: 29137966
[TBL] [Abstract][Full Text] [Related]
13. Differential long-term outcomes of zotarolimus-eluting stents compared with sirolimus-eluting and paclitaxel-eluting stents in diabetic and nondiabetic patients: two-year subgroup analysis of the ZEST randomized trial.
Jang SJ; Park DW; Kim WJ; Kim YH; Yun SC; Kang SJ; Lee SW; Lee CW; Park SW; Park SJ
Catheter Cardiovasc Interv; 2013 Jun; 81(7):1106-14. PubMed ID: 22899589
[TBL] [Abstract][Full Text] [Related]
14. 5-Year Outcome Following Randomized Treatment of All-Comers With Zotarolimus-Eluting Resolute Integrity and Everolimus-Eluting PROMUS Element Coronary Stents: Final Report of the DUTCH PEERS (TWENTE II) Trial.
Zocca P; Kok MM; Tandjung K; Danse PW; Jessurun GAJ; Hautvast RWM; van Houwelingen KG; Stoel MG; Schramm AR; Tjon Joe Gin RM; de Man FHAF; Hartmann M; Louwerenburg JHW; Linssen GCM; Löwik MM; Doggen CJM; von Birgelen C
JACC Cardiovasc Interv; 2018 Mar; 11(5):462-469. PubMed ID: 29519378
[TBL] [Abstract][Full Text] [Related]
15. Rationale and design of amphilimus sirolimus-eluting stents versus zotarolimus-eluting stents in all-comers requiring percutaneous coronary intervention (ReCre8): A multicenter randomized clinical trial.
Rozemeijer R; Stein M; Frambach P; Voskuil M; Kraaijeveld AO; Rodríguez-Olivares R; Timmers L; Pereira B; Rittersma SZ; Agostoni P; Doevendans PA; Stella PR
Catheter Cardiovasc Interv; 2018 Feb; 91(3):410-416. PubMed ID: 28544782
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
